CYP19A1 and breast carcinoma: STAT1 drives aromatase inhibitor resistance in breast cancer, and is highly expressed in estrogen receptor-positive, tamoxifen-resistant breast cancer cell lines, indicating it may be a promising target in this malignancy[59].